Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$423.33 USD

423.33
207,247

+5.48 (1.31%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $424.08 +0.75 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

EHC vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

    Zacks Equity Research

    EHC vs. CHE: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    EHC vs. CHE: Which Stock Is the Better Value Option?

      Zacks Equity Research

      STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

      by Zacks Equity Research

      STERIS (STE) continues to gain from strength in all business segments in Q1.

        Zacks Equity Research

        Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates

        by Zacks Equity Research

        Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.

          Zacks Equity Research

          Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View

          by Zacks Equity Research

          Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.

            Zacks Equity Research

            Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2

            by Zacks Equity Research

            Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.

              Zacks Equity Research

              CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up

              by Zacks Equity Research

              CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.

                Zacks Equity Research

                BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top

                by Zacks Equity Research

                A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.

                  Zacks Equity Research

                  Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up

                  by Zacks Equity Research

                  Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.

                    Zacks Equity Research

                    Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View

                    by Zacks Equity Research

                    Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                      Zacks Equity Research

                      Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish

                      by Zacks Equity Research

                      Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.

                        Zacks Equity Research

                        Luminex (LMNX) Misses on Earnings in Q2, Margins Contract

                        by Zacks Equity Research

                        Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.

                          Zacks Equity Research

                          Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag

                          by Zacks Equity Research

                          We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.

                            Zacks Equity Research

                            Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up

                            by Zacks Equity Research

                            All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.

                              Zacks Equity Research

                              Cardinal Health (CAH) Surpasses Earnings Estimates in Q4

                              by Zacks Equity Research

                              Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.

                                Zacks Equity Research

                                Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand

                                by Zacks Equity Research

                                Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.

                                  Zacks Equity Research

                                  Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates

                                  by Zacks Equity Research

                                  Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.

                                    Zacks Equity Research

                                    Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y

                                    by Zacks Equity Research

                                    Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.

                                      Zacks Equity Research

                                      Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates

                                      by Zacks Equity Research

                                      We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.

                                        Zacks Equity Research

                                        ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth

                                        by Zacks Equity Research

                                        ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.

                                          Zacks Equity Research

                                          PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates

                                          by Zacks Equity Research

                                          PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.

                                            Zacks Equity Research

                                            PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up

                                            by Zacks Equity Research

                                            Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.

                                              Zacks Equity Research

                                              IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up

                                              by Zacks Equity Research

                                              IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.

                                                Zacks Equity Research

                                                NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down

                                                by Zacks Equity Research

                                                NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.

                                                  Zacks Equity Research

                                                  Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips

                                                  by Zacks Equity Research

                                                  At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.